AI assistant
Sending…
bioAffinity Technologies, Inc. — Director's Dealing 2024
Jul 3, 2024
35439_dirs_2024-07-02_ddc0e47d-88ca-4259-80dc-8e70c6d6c62d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: bioAffinity Technologies, Inc. (BIAF)
CIK: 0001712762
Period of Report: 2024-07-01
Reporting Person: GIRGENTI STEVEN (Director, Executive Chairman)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-07-01 | Common Stock | A | 33784 | — | Acquired | 1065248 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 8955 | Indirect |
Footnotes
F1: Grant of restricted shares of common stock, par value $0.007 per share, that vest pro rata on a monthly basis for 12 months commencing on August 1, 2024.
F2: These shares are owned directly by the Cranye Girgenti Testamentary Trust (the "Trust"). The reporting person is a co-trustee of the Trust. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
More from bioAffinity Technologies, Inc.
Regulatory Filings
2026
Jun 2
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 20
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 12
Earnings Release
2026
May 8
Regulatory Filings
2026
Apr 30
Regulatory Filings
2026
Apr 14
Regulatory Filings
2026
Apr 7
Investor Presentation
2026
Mar 26